Navigation Links
Frost & Sullivan to Host Analyst Briefing on the European Orphan Diseases Market: Niche-Busters - An Attractive Future?
Date:1/26/2009

LONDON, Jan. 26 /PRNewswire/ -- The Healthcare Group at Frost & Sullivan is pleased to announce its 2009 Quarterly Analyst Briefing Presentation on the European Orphan Diseases Market to be held on Thursday, 5 February, 2009 at 2 p.m. GMT.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

Today's pharmaceutical companies are facing a tough competition in the generics market because of the patent expiry of blockbuster molecules. CEOs have had to re-think and take alternative options to maintain the growth of the organization and to satisfy the stakeholders. One of these alternative options is the Niche buster market. There has been good growth in the orphan diseases market because of various incentives and benefits provided by the governments. Especially in the European Union this emerging market ensures a return on investment.

The briefing on the European Orphan Diseases Market will benefit pharmaceutical companies, biopharmaceutical companies which develop drugs for orphan diseases and university spin-off drug developers.

"The future is likely to witness major consolidation due to mergers and acquisitions among the big pharmaceuticals and small biotech companies." notes Frost & Sullivan Programme Leader Shabeer Hussain. "Lack of investment to bring out newer therapies and technologies has been a major challenge for the small biotechnology companies".

Frost & Sullivan will hold this conference call at 2 p.m. GMT on Thursday, 5 February, 2009, which will provide industry participants an outlook of the European Orphan Diseases Market. To participate, please email Katja Feick at katja.feick@frost.com with the following informat
'/>"/>

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Supernanny Jo Frost Joins the Partnership for a Drug-Free America in Supporting Time To Talk(TM)
2. Masimo Corporation Receives a Frost & Sullivan 2007 Industry Best Practices Award for Pulse Oximetry Leadership
3. Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award
4. Novadaqs SPY Imaging System named Product of the Year by Frost and Sullivan
5. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
6. Kelloggs Frosted Flakes Gold(TM) Helps Moms Get the Gold
7. MedApps Receives Prestigious Frost & Sullivan Award
8. Nancy Frost Joins Lawson-Hawks as Employee Benefits Vice President
9. Accurays CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan
10. Help Your Kids Earn an A for Attentiveness with a Bowl of Frosted Mini- Wheats(R) Cereal for Breakfast
11. Therapy Could Save Limbs After Frostbite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Market Publishers Ltd announces that ... added to its catalogue. , Pharmaceutical ... Contract Research and Manufacturing Services (CRAMS), Biosimilars, Generics ... include, among others, increasing ageing population, rising incomes ... the pharma market in India is anticipated to ...
(Date:8/1/2014)... Patients with the progressive, deadly respiratory ailment known as ... to battle the disease, the U.S. Food and Drug ... new treatment, an inhaled spray called Striverdi Respimat (olodaterol) ... which is often linked to smoking, involves multiple lung ... Patients with COPD may experience a number of symptoms, ...
(Date:8/1/2014)... North America Endpoint Security Market report defines and segments ... analysis and forecast of revenue. This market is estimated ... $4.77 billion by 2019, at a CAGR of 6.2% ... of the North America Endpoint Security Market report to ... also provides a glimpse of the segmentation in market, ...
(Date:8/1/2014)... Scientists at Albert Einstein College of Medicine ... in digestion help keep the intestinal lining intact. The ... could yield new therapies for inflammatory bowel disease (IBD) ... research involved the intestinal microbiome, which contains some 100 ... or preventing disease is a major emerging field of ...
(Date:8/1/2014)... By Kathleen Doheny ... (HealthDay News) -- Birth control pills containing high doses ... the risk of breast cancer in women under 50, ... oral contraceptive formulations," explained lead researcher Elisabeth Beaber, a ... in Seattle. "Some of these formulations increase breast cancer ...
Breaking Medicine News(10 mins):Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 3Health News:FDA Approves New Treatment for People With COPD 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:'Normal' bacteria vital for keeping intestinal lining intact 2Health News:Some Birth Control Pills May Up Breast Cancer Risk 2Health News:Some Birth Control Pills May Up Breast Cancer Risk 3
... women around the world, including an estimated 50,000 in ... by Georgetown University Medical Centers Institute for Reproductive Health. ... CycleBeads a visual aid developed by the Institute to ... pregnancy. , Now CycleBeads are available in a ...
... Dermatologist says ,I am revolted by it;, Petitions ... Feb. 4 A group of,dermatologists, including Dr. ... of Dermatopathology in New York City, has called ... program a,"shocking conflict of interest." The AAD agreed ...
... Feb. 4 Sage Software today announced that,Navarre Avenue ... by,Sage for the practice,s Electronic Health Records needs., ... this,year, according to Joni Tarver, Office Manager of Navarre ... practice,s rapid growth and,lack of chart space prompted the ...
... use, WASHINGTON, Feb. 4 The use ... the levels of phthalates,found in the babies, urine, ... researchers published today in Pediatrics Journal., In ... malformations of the male reproductive tract. Several human ...
... the world of organ donation, it has been common practice ... donor supply and lower survival rates. ... successful lung transplant at 65, are proving that perhaps age ... UCLA Medical Center study shows that select patients age 65 ...
... for Sharps Disposal by Mail System(R) and other products reach $3.8 ... by growth in pharmaceutical and hospitality markets - Strong operating leverage ... $400 thousand also expected in third ... quarter fiscal 2008, - ...
Cached Medicine News:Health News:CycleBeads help women manage their fertility 2Health News:American Academy of Dermatology Caught in Pay-for-Play Scandal 2Health News:Ohio Obstetrics and Gynecology Practice Selects Intergy EHR by Sage Electronic Health Record System 2Health News:Chemical Linked to Reproductive Harm Is Getting Into Babies From Shampoo, Lotion and Powder, New Study Suggests 2Health News:Study finds good outcomes for older lung transplant patients 2Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 2Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 3Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 4Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 5Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 6Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 7Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 8Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 9Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 10Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 11Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 12
(Date:7/31/2014)... 31, 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... for the quarter ended June 30, 2014. Financial ... 2014 Revenue Total revenue for the quarter ended June ... the quarter ended June 30, 2013 primarily due to IMBRUVICA ... Total revenue for the six months ended June ...
(Date:7/31/2014)... Therapeutics (Nasdaq: NKTR ) today reported its financial ... Cash and investments in marketable securities at June ... at March 31, 2014."The second half of 2014 will be ... significant milestones for a number of our late-stage clinical programs," ... Nektar. "The first of these is the potential US and ...
(Date:7/31/2014)... , July 31, 2014   Auxilium Pharmaceuticals , ... specialty biopharmaceutical company, today announced that the Company will ... Thursday, August 7, 2014 before the opening of the ... conference call that day at 8:30 a.m. ET to ... 2014. The presentation slides to be used during the ...
Breaking Medicine Technology:Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9
... and Oncomine Concepts Map Integral in Expression and Association ... ... Building on an earlier study,that used Oncomine(TM) to identify ETS-fusion proteins in ... of,four additional classes of ETS rearrangements in prostate cancer, each of,which activates ...
... Va., Aug. 2 The American Society,for Therapeutic ... for Lymphoma, a short treatment guide to assist ... outlines the major,differences between the diseases, explains radiation ... before, during and after radiation,therapy. "A cancer ...
Cached Medicine Technology:Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications 2
... The model 55S Rocking Shaker ... gels and blotted membranes. The very ... adjustable degree of tilt provide a ... washes over gels and blotted membranes ...
... The model 55S Rocking Shaker ... gels and blotted membranes. The very ... adjustable degree of tilt provide a ... washes over gels and blotted membranes ...
Multi-Tier Shaker...
... The Thermo Labsystems Wellmix is a ... and time settings. The shaking speed is ... shaking frequency, high speed and a small ... assays. The shaking time is quick and ...
Medicine Products: